Head-to-head · free
Rapport Therapeutics vs Rhythm Pharmaceuticals, Inc.
RAPP vs RYTM — return on capital, cash generation, margins and balance sheet side by side.
RAPP
3 / 4
measures where RAPP leads
RYTM
1 / 4
measures where RYTM leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | RAPP · FY2025 | RYTM · FY2025 |
|---|---|---|
| Revenue | — | $189.8M |
| Net income | (111.5M) | (196.5M) |
| Revenue growth (yearly, multi-year) | — | 56.5% |
| Free cash flow | (88.1M) | (116.6M) |
| Free cash flow margin | — | -61.5% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -28.2% | -251.1% |
| Gross margin | — | 89.7% |
| Operating margin | — | -101.2% |
| Net debt / EBITDA | 0.42x | 0.28x |
Figures are as reported by each company; latest fiscal year shown.
Where Rapport Therapeutics's cash went (FY2025)
- Capital spending
- $616000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Rhythm Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $953000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free